#Eli Lilly

Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.

The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. The retatrutide MASLD Phase 3 (NCT06859268) is enrolling, building on 86% Phase 2 liver-fat reduction. LillyDirect handles self-pay distribution.

The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. June 2026 forced a manufacturing geography rethink: Lilly halved its planned €2.3 billion ($2.7B) Alzey, Rhineland-Palatinate injectable plant to roughly €1.15 billion and cut planned headcount from 1,000 to 500, citing Germany's proposed 'dynamic manufacturer rebate' and the broader healthcare-reform package. The redirected capital is heading to US sites, most likely Lilly's Pennsylvania facility, alongside the previously announced $4.5 billion Indiana 'Medicine Foundry' R&D and manufacturing project. Boehringer Ingelheim is making a parallel German cut. The Alzey scale-back arrived the same week as STAT News' June 23 disclosure that the FDA and Lilly granted compassionate-use retatrutide access to a 79-year-old patient on the application of NIH senior clinician Dr. Ranganath Muniyappa, with the White House publicly denying that President Trump applied. Stories here track the pipeline, deals, manufacturing geography, and the share-price moves that follow them.